MAML2 negative oncocytic mucoepidermoid carcinoma of submandibular gland
Surgical and Experimental Pathology volume 5, Article number: 17 (2022)
Oncocytic mucoepidermoid carcinoma is a rare variant of mucoepidermoid carcinoma. Only a few cases are reported involving mostly the parotid gland with only four cases reported in the submandibular gland. Mastermind-like 2 (MAML2) translocation is detected in about 66% mucoepidermoid carcinoma and many oncocytic mucoepidermoid carcinoma.
We present a rare case of MAML2 negative oncocytic mucoepidermoid carcinoma of the submandibular gland in a 73-year-old female. CT revealed a large left submandibular gland mass. Submandibular gland resection with marginal mandibulectomy and ipsilateral neck dissection was performed. Grossly, a solid-cystic submandibular gland tumor was identified. Microscopic examination revealed an infiltrative proliferation of oncocytes. Foci of squamoid and intermediate cells with rare mucocytes were present. Two ipsilateral cervical lymph nodes and mandible were involved. Immunohistochemistry and special stains demonstrated positivity for p63, p40, CK5/6, mucicarmine and alcian blue. No MAML2 gene rearrangement was identified.
An awareness that MAML2 negative mucoepidermoid carcinoma exists will prevent misdiagnosis and incorrect treatment as many of its differential diagnoses are benign.
Mucoepidermoid carcinoma (MEC) is the most common malignant salivary gland tumor (D'Antonio et al., 2015). MEC consists of squamoid cells, intermediate cells, and mucous cells in varying proportions (Liao et al., 2016). MEC may occasionally show presence of other cell types including clear cells and oncocytes. The diagnosis becomes challenging when these cells predominate (Luna, 2006; Coca-Pelaz et al., 2015; Gill et al., 2017). Oncocytic mucoepidermoid carcinoma (OMEC) has a predominance of oncocytes with no well-defined percentage (Weinreb et al., 2009). OMEC is a rare variant. Only a few cases have been reported involving mostly the parotid gland. Submandibular gland is a rare site for OMEC with only four cases reported in the English literature (Corcione et al., 2007; Krishnanand et al., 2007; Jing et al., 2012; Avila et al., 2019). Table 1 summarizes them. Mastermind-like 2 (MAML2) translocation is detected in about 66% MEC and many oncocytic MEC (Seethala et al., 2010; García et al., 2011). Skalova et al. found only MAML2 rearranged OMEC with no MAML2 negative OMEC in their study (Skálová et al., 2020). However, Garcia et al. found 4 out of 14 OMEC that were MAML2 negative. All 14 of their cases were parotid tumors (García et al., 2011). We report a rare case of MAML2 negative oncocytic MEC of the submandibular gland. To the best of our knowledge MAML2 negative OMEC has not been reported in the submandibular gland.
We present a rare case of MAML2 negative OMEC of the submandibular gland in a 73-year-old female with an 11-month history of a left neck mass. CT revealed a large centrally necrotic left submandibular gland mass with a thick enhancing soft tissue rim. Fine-needle aspiration cytology confirmed malignancy. Left submandibular gland resection with marginal mandibulectomy and ipsilateral neck dissection was performed.
Grossly, a circumscribed, solid-cystic tumor measuring 13.5 × 11 × 4.5 cm, arising from the submandibular gland was identified. Microscopic examination revealed an un-encapsulated and infiltrative proliferation of oncocytes forming cords, nests, and sheets. The oncocytes were polygonal in shape and revealed abundant eosinophilic and granular cytoplasm with centrally located nuclei having prominent nucleoli (Fig. 1A, B & C). Tubulocystic areas with rare vacuolated cells and foci of squamoid and intermediate cells were present (Fig. 1D, E & F). A diagnosis of mucoepidermoid carcinoma, intermediate grade, with features of pure oncocytic variant was made. No perineural invasion was identified. Two ipsilateral cervical lymph nodes and mandible were involved. Mucicarmine and alcian blue special stains demonstrate rare intraluminal and intracytoplasmic mucin (Fig. 2A & B). Immunohistochemical (IHC) stains demonstrated immunoreactivity for p63 (diffuse; Fig. 3A), p40 (Fig. 3B), CK5/6 (diffuse, Fig. 3C), and weak and rare immunoreactivity for GATA 3 and GCDFP-15. No immunoreactivity was seen for CK7, calponin, S-100, TTF-1, and thyroglobulin, supporting our diagnosis and ruling out salivary duct carcinoma, mammary analog secretory carcinoma, plasmacytoid myoepithelioma, and metastatic thyroid neoplasm. Table 2 shows specifications of IHC antibodies used. No rearrangement of the MAML2 gene on fluorescent in-situ hybridization testing was identified, when tested at two independent centers. Rearrangements of the MAML2 gene on 11q21 were evaluated using MAML2 break-apart FISH probes (Empire Genomics, Buffalo, NY) on formalin-fixed and paraffin-embedded (FFPE) tissue slides.
The patient also had co-morbidities including HCV infection, cirrhosis, coronary artery disease with stent placement and hypertension. She presented 10 days after discharge with left femoral neck fracture and underwent left hip hemiarthroplasty. The pathologic examination revealed signs of fracture without any pathology in the bone. A month later she had right femoral neck fracture which was surgically repaired. Patient tolerated the procedure well and was admitted to the floor. Five days later patient clinically declined and found to be in septic shock secondary to C. difficile colitis. Total abdominal colectomy was performed. However, patient continued to clinically decline and expired the next day.
Discussion and conclusion
MEC is composed of squamoid, intermediate and mucous cells in varying proportions. Other cell types that could be found are clear cells, columnar cells, goblet cells, and oncocytes (Qayoom et al., 2021). Occasionally, clear cells and oncocytes predominate with rare mucinous cells which are the only clue to the diagnosis of MEC. Such cases pose a diagnostic challenge for pathologists. OMEC presents in the age range of 20 to 80 years with a male predilection (Kwon et al., 2010). Most are cystic and have a favourable prognosis (Weinreb et al., 2009). OMEC can be mimicked by many benign and malignant neoplasms, including oncocytoma, oncocytic variant of cystadenoma, oncocytic carcinoma, myoepithelioma, oncocytic pleomorphic adenoma, metaplastic Warthin’s tumor, salivary duct carcinoma, and metastatic renal cell carcinoma. Distinguishing these from OMEC is imperative due to prognostic differences. P63 is considered a potential marker that could differentiate between these entities. The epidermoid/squamoid cells of OMEC are immunoreactive for p63. Oncocytomas and oncocytic carcinoma are also p63, however, the staining pattern is predominantly peripheral/basal (McHugh et al., 2007). Metastatic renal cell carcinoma is p63 negative (McHugh et al., 2007). Myoepithelioma and squamous cell carcinoma stain diffusely with p63 but both lack mucin-producing cells. Myoepithelioma also stains for other myoepithelial markers, such as calponin and actin. Warthin’s tumors typically don’t have mucous cells or intercellular bridges in the oncocytic cells and are non-infiltrative (Weinreb et al., 2009). Pleomorphic adenomas have chondro-myxoid stroma and are generally non-infiltrative (Skálová et al., 1999). The Table 3 summarises the differential diagnosis of OMEC.
Rearrangement in MAML2 gene, a component of the Notch signaling pathway, has been promising in diagnosing MEC and its variants accurately. MAML2 translocation by FISH is detected in approximately 66% typical MEC cases and about 71% of oncocytic MEC (Liao et al., 2016; García et al., 2011). In contrast, most of the imitators of MEC are negative for MAML2 translocation. Thus, Liao et al. suggested that MAML2 translocation can be used as a diagnostic tool to detect OMEC. However, our case of MAML2 negative OMEC introduces an important consideration that MAML2 negative OMEC do exist, and the diagnosis should not be solely based on the presence of MAML2 translocation.
Previous studies considered MAML2 to confer a favourable prognosis (Seethala et al., 2010). However, recently the prognostic significance of MAML2 rearrangement has been challenged (Skálová et al., 2020). Our case, which was MAML2 negative, had an aggressive course with spread to mandible bone and regional lymph nodes.
In summary, we present a rare case of MAML2 negative OMEC of the submandibular gland composed primarily of oncocytes with only rare mucous cells, epidermoid cells and intermediate cells. Further studies are required to understand the pathogenesis of MEC and the prognostic significance of MAML2 rearrangement in its pathogenesis. An awareness that MAML2 negative OMEC exists will prevent misdiagnosis and incorrect treatment as many of the differential diagnoses of OMEC are benign.
Availability of data and materials
Oncocytic Mucoepidermoid carcinoma
Avila RE, Samar ME, Ferraris R, La Rosa FG. Oncocytic mucoepidermoid carcinoma of the submandibular salivary gland: a challenging differential diagnosis of a very rare tumor. Ann Clin Case Rep. 2019;4:1726.
Coca-Pelaz A, Rodrigo JP, Triantafyllou A, Hunt JL, Rinaldo A, Strojan P, Haigentz M Jr, Mendenhall WM, Takes RP, Vander Poorten V, Ferlito A. Salivary mucoepidermoid carcinoma revisited. Eur Arch Otorhinolaryngol. 2015;272(4):799–819. https://doi.org/10.1007/s00405-014-3053-z Epub 2014 Apr 26. PMID: 24771140.
Corcione L, Giordano G, Gnetti L, Multinu A, Ferrari S. Oncocytic mucoepidermoid carcinoma of a submandibular gland: a case report and review of the literature. Int J Oral Maxillofac Surg. 2007;36(6):560–3. https://doi.org/10.1016/j.ijom.2006.12.017 Epub 2007 Feb 28. PMID: 17331704.
D'Antonio A, Boscaino A, Caleo A, Addesso M, Orabona P. Oncocytic variant of mucoepidermoid carcinoma: a diagnostic challenge for the pathologist. Indian J Pathol Microbiol. 2015;58(2):201–3. https://doi.org/10.4103/0377-4929.155315 PMID: 25885134.
García JJ, Hunt JL, Weinreb I, McHugh JB, Barnes EL, Cieply K, Dacic S, Seethala RR. Fluorescence in situ hybridization for detection of MAML2 rearrangements in oncocytic mucoepidermoid carcinomas: utility as a diagnostic test. Hum Pathol. 2011;42(12):2001–9. https://doi.org/10.1016/j.humpath.2011.02.028 Epub 2011 Jul 20. PMID: 21777943.
Gill I, Brezina L, Siddiqi J. Unexpected case of sclerosing mucoepidermoid carcinoma of the submandibular salivary gland. Br J Oral Maxillofac Surg. 2017;55(6):646–7. https://doi.org/10.1016/j.bjoms.2017.02.004 Epub 2017 Feb 28. PMID: 28256279.
Jing H, Meng Q, Tai Y. Oncocytic mucoepidermoid carcinoma with prominent tumour-associated lymphoid proliferation of the submandibular gland. Oral Oncol. 2012;48(2):e7–8. https://doi.org/10.1016/j.oraloncology.2011.09.009 Epub 2011 Oct 5. PMID: 21978535.
Krishnanand G, Kaur M, Rao RV, Monappa V. Oncocytic variant of mucoepidermoid carcinoma of submandibular gland: an unusual clinical and morphological entity. Indian J Pathol Microbiol. 2007;50(3):538–40 PMID: 17883126.
Kwon H, Lim W, Choi Y, Nam J, Han C, Kim J, Ko Y, Kim I, Kim S, Kim M, Kim O, Choi H, Kim O. High-grade oncocytic mucoepidermoid carcinoma of the minor salivary gland origin: a case report with immunohistochemical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109(6):e72–7. https://doi.org/10.1016/j.tripleo.2010.01.026 PMID: 20451836.
Liao X, Haghighi P, Coffey CS, Xu X. A rare case of exclusively Oncocytic Mucoepidermoid carcinoma with MAML2 translocation. Rare Tumors. 2016;8(2):6166. https://doi.org/10.4081/rt.2016.6166 PMID: 27441073; PMCID: PMC4935822.
Luna MA. Salivary mucoepidermoid carcinoma: revisited. Adv Anat Pathol. 2006;13(6):293–307. https://doi.org/10.1097/01.pap.0000213058.74509.d3 PMID: 17075295.
McHugh JB, Hoschar AP, Dvorakova M, Parwani AV, Barnes EL, Seethala RR. p63 immunohistochemistry differentiates salivary gland oncocytoma and oncocytic carcinoma from metastatic renal cell carcinoma. Head Neck Pathol. 2007;1(2):123–31. https://doi.org/10.1007/s12105-007-0031-4 Epub 2007 Oct 26. PMID: 20614263; PMCID: PMC2807526.
Qayoom S, Singh AK, Chakrabarti D, Singh HP, Singh US. Oncocytic mucoepidermoid carcinoma (OMEC) of the parotid gland in a 12-year-old patient: a diagnostic challenge on cytology. Diagn Cytopathol. 2021;49(2):E60–4. https://doi.org/10.1002/dc.24581 Epub 2020 Aug 15. PMID: 33237638.
Seethala RR, Dacic S, Cieply K, Kelly LM, Nikiforova MN. A reappraisal of the MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas. Am J Surg Pathol. 2010;34(8):1106–21. https://doi.org/10.1097/PAS.0b013e3181de3021 PMID: 20588178.
Skálová A, Agaimy A, Stanowska O, Baneckova M, Ptáková N, Ardighieri L, Nicolai P, Lombardi D, Durzynska M, Corcione L, Laco J, Koshyk O, Žalud R, Michal M, Vanecek T, Leivo I. Molecular profiling of salivary Oncocytic Mucoepidermoid carcinomas helps to resolve differential diagnostic dilemma with low-grade Oncocytic lesions. Am J Surg Pathol. 2020;44(12):1612–22. https://doi.org/10.1097/PAS.0000000000001590 PMID: 33002921.
Skálová A, Michal M, Ryska A, Simpson RH, Kinkor Z, Walter J, Leivo I. Oncocytic myoepithelioma and pleomorphic adenoma of the salivary glands. Virchows Arch. 1999;434(6):537–46. https://doi.org/10.1007/s004280050381 PMID: 10394890.
Weinreb I, Seethala RR, Perez-Ordoñez B, Chetty R, Hoschar AP, Hunt JL. Oncocytic mucoepidermoid carcinoma: clinicopathologic description in a series of 12 cases. Am J Surg Pathol. 2009;33(3):409–16. https://doi.org/10.1097/PAS.0b013e318184b36d PMID: 18971778.
Ethics approval and consent to participate
Submission declaration and verification
Parts of this article were previously presented as an abstract/poster at CAP 2021 virtual abstract program.
Consent for publication
Not applicable (no identifying information is present in the case report).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kamal, M., Afzal, A. & Gillies, E. MAML2 negative oncocytic mucoepidermoid carcinoma of submandibular gland. Surg Exp Pathol 5, 17 (2022). https://doi.org/10.1186/s42047-022-00119-5
- Oncocytic mucoepidermoid carcinoma
- Submandibular gland